Lupin Launches Generic Atovaquone Oral Suspension USP in the US

Pharma major Lupin announced the launch of Atovaquone Oral Suspension USP, 750 mg/5 mL having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Atovaquone Oral Suspension USP, 750 mg/5 mL is the generic equivalent of Glaxosmithkline LLC’s Mepron oral suspension 750 mg/5 mL. It is indicated for the prevention of Pneumocystis jirovecii pneuomonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprimsulfamethoxazole (TMP-SMX). It is also for the treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX. Atovaquone Oral Suspension USP, 750 mg/5 mL had annual sales of approximately USD 119 million in the US (IQVIA MAT September 2018). – Medical Buyer Bureau